Venker Eric

Venker Eric, chief executive officer of both Immunovant (IMVT) and Roivant Sciences (ROIV), has filed 77 Form 4 transactions across the two companies, with a total sell value of $140.1 million and no open-market purchases on record. The pattern is uniformly dispositional. Every trade in the recent window is a sale, an option exercise paired with a sale, a tax withholding, or a return of shares to the issuer. There is no acquisition code, no grant, and no buy in the last 11 filings. The most active selling has been in ROIV. On September 30, 2026, Venker exercised options worth $770,000 and sold shares for $7.3 million. A similar structure appeared on August 28, with a $770,000 exercise followed by two sales totaling $7.2 million. July 27 brought another $770,000 exercise and a $6.99 million sale. The same cadence repeated on June 24, May 22, and April 20, each with a $770,000 exercise and a sale between $1.5 million and $6.1 million. Tax withholding events on August 20 and May 20 added $512,407 and $1.1 million in non-discretionary dispositions. IMVT activity is smaller but follows the same direction. On October 2, 2026, Venker sold $119,589 worth of stock. The day before, he exercised options valued at $1.33 million and returned $2.89 million in shares to the issuer. The same pairing occurred on July 1, with a $1.33 million exercise and a $3.3 million return. A $34,661 sale on April 2 and two zero-value grants on April 7 round out the recent IMVT filings. Across both tickers, the data shows a consistent pattern of monetization through exercises and sales, with no counterbalancing purchases.